Biochanin A (Isoflavone · Genistein Prodrug · Hormonal Balance)

Compound	Biochanin A
Chemical class	Polyphenol — Isoflavone (4′-Methylgenistein)
CAS	491-80-5
Primary source	Trifolium pratense (red clover), Cicer arietinum (chickpea)
Key applications	Hormonal balance, demethylates to genistein in vivo, neuroprotective
Claim strength	Moderate
Typical form	Red clover isoflavones extract (standardised to total isoflavones)
Buy from Herbuno	Red Clover Isoflavones 40% Powder (Red Clover Extract) | Standardized Trifolium pratense → Red Clover Isoflavones 20% Powder (Red Clover Extract) | Standardized Trifolium pratense →

Name origin: Biochanin A was named after Bicha — an archaic name for red clover — when first isolated from this plant. It is the 4′-O-methyl ether of genistein — genistein with a methyl group replacing the 4′-hydroxyl, reducing direct estrogenic activity but creating a prodrug that is demethylated to genistein in vivo. Traditional use: Red clover (Trifolium pratense) has been used in European phytomedicine as a women’s health herb and expectorant. The isoflavone-rich aerial parts are the commercial extract source. Research trajectory: Biochanin A has dual research relevance: as a genistein prodrug (its primary metabolic fate) and as a bioactive compound in its own right with neuroprotective, anti-inflammatory, and potential neurodegeneration-relevant mechanisms distinct from genistein. Commercial source: Biochanin A is commercially available as a primary co-constituent of red clover (Trifolium pratense) isoflavone extract standardised to 20% and 40% total isoflavones. See sourcing options below.

---

Evidence for Biochanin A Applications

Hormonal balance and menopausal support (via genistein conversion): Biochanin A is demethylated to genistein by intestinal and hepatic CYP450 enzymes and gut microbiota. Clinical trials of red clover isoflavone extract (delivering biochanin A + formononetin + daidzein + genistein) demonstrate hot flush reduction and bone density maintenance in menopausal women. Biochanin A’s contribution is partially through its genistein conversion. Claim strength: Moderate.

Neuroprotective activity: Biochanin A independently inhibits neuroinflammation (microglial NF-κB activation), reduces amyloid-beta aggregation in cell models, and protects dopaminergic neurons in Parkinson’s disease models. These activities are distinct from genistein and suggest biochanin A has direct neuroprotective utility beyond its prodrug role. Claim strength: Emerging.

Anti-inflammatory and aromatase modulation: Biochanin A inhibits aromatase (CYP19A1) and COX-2 in cell-based assays, with dual hormonal and anti-inflammatory relevance for women’s health formulations. Lower direct estrogenic activity than genistein makes it potentially more suitable for some hormone-sensitive contexts. Claim strength: Moderate.

---

Dosage & Formulator Specification

Red clover isoflavone clinical trials (Promensil® and similar products): 40–160 mg/day total isoflavones (biochanin A + formononetin + daidzein + genistein combined). For Herbuno’s Red Clover Isoflavones 40% extract, 100–200 mg/day extract delivers 40–80 mg total isoflavones, with biochanin A typically constituting 30–50% of the red clover isoflavone fraction.

Red clover isoflavone profile differs from soy: red clover provides predominantly methylated forms (biochanin A, formononetin) that require demethylation in vivo; soy provides predominantly the aglycones (genistein, daidzein). This metabolic step introduces variability; enzyme inducers or inhibitors affecting CYP1A2 may alter biochanin A to genistein conversion rate.

Specify total isoflavone content (HPLC) with individual reporting of biochanin A, formononetin, genistein, and daidzein for premium red clover extract sourcing. Biochanin A is relatively stable in standard extract formats; no special delivery enhancement required for the prodrug conversion step.

---

Frequently Asked Questions — Biochanin A

Is red clover extract better than soy extract for menopausal support?
Both have clinical evidence. Red clover delivers a four-isoflavone profile (biochanin A, formononetin, daidzein, genistein) that provides broader coverage. Some trials show red clover extract superior to soy for hot flush management, possibly due to the formononetin—daidzein—equol cascade providing additional phytoestrogenic activity. The choice depends on formulation goals and target population.

Does the methyl group on biochanin A make it less estrogenic than genistein?
Yes, directly. The 4′-methyl ether eliminates direct phenolic hydroxyl interaction with the oestrogen receptor. Biochanin A is a weak direct ER ligand. Its estrogenic activity in vivo is largely attributable to genistein conversion. For applications requiring reduced direct estrogenic activity with preserved systemic isoflavone exposure, biochanin A has theoretical utility over genistein aglycone.

Can biochanin A be included in a nootropic or brain health formulation?
The emerging neuroprotective evidence (neuroinflammation, amyloid-beta, dopaminergic protection) provides a rationale for biochanin A inclusion in cognitive health or brain ageing formulations. Red clover extract at 100–200 mg/day as a biochanin A source is a practical approach. Position as “supporting healthy neuroinflammatory balance” consistent with the preclinical evidence base.

Does biochanin A affect drug metabolism via CYP enzymes?
Biochanin A is itself a CYP1A2 substrate (for demethylation to genistein) and may modestly inhibit CYP1A2 at higher concentrations. This could affect metabolism of other CYP1A2 substrates (caffeine, certain antidepressants, theophylline) at high red clover extract doses. At standard supplement doses (40–80 mg total isoflavones/day), clinically significant interactions are considered unlikely.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery